Gökçen Telli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gökçen Telli has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Bülent Gümüşel
Okan Üniversitesi
2 shared publications - Inci Kazkayasi
Hacettepe University, Faculty of Pharmacy, Department of Pharmacology, Ankara, Turkey
2 shared publications - Akile Zengin
Department of Gastrointestinal Surgery, Eskisehir Osmangazi University, Eskisehir, Turkey
1 shared publication - Alba Vera-Zambrano
Instituto de Investigaciones Biomédicas Sols-Morreale, IIBM, CSIC-UAM, Madrid, Spain; Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Spain
1 shared publication Angel Cogolludo
Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain
1 shared publication- Açelya Erikçi
Lokman Hekim Universitesi
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Ataturk Universitesi in Pharmata
- Vol. 6 (3) , 154-164
A New Era in Therapeutics: Current Status of RNA Interference-Based Drugs
RNA interference (RNAi) is a post-transcriptional gene silencing mechanism that regulates gene expression through sequence-specific degradation or translational inhibition of mRNA. Since its discovery, RNAi has emerged as a powerful therapeutic strategy due to its ability to selectively silence disease-causing genes that are often inaccessible to conventional small-molecule drugs. The clinical efficacy of RNAi technology is evidenced by the approval of multiple siRNA-based therapeutics for the treatment of various diseases. These include patisiran and vutrisiran for hereditary transthyretin amyloidosis, inclisiran for hypercholesterolemia, fitusiran for haemophilia A and B, givosiran for acute hepatic porphyria, and lumasiran and nedosiran for primary hyperoxaluria. Concurrently, a significant number of RNAi therapeutics are currently undergoing clinical trials for metabolic, cardiovascular, neurological, renal, pulmonary diseases and oncological area. Despite these advances, the clinical translation of RNAi therapeutics is limited by several challenges, including off-target effects, immune activation, and difficulties associated with efficient and targeted delivery. Ongoing research focuses on improving siRNA design, chemical modification, and delivery strategies in order to enhance specificity, reduce immunogenicity, and achieve effective delivery to target tissues. In conclusion, RNA interference has become more significant and expanding therapeutic approach with considerable implications for future drug development.
- 13 November 2026
- Published by Ataturk Universitesi in Pharmata
- Vol. 6 (3) , 154-164
Open AccessA New Era in Therapeutics: Current Status of RNA Interference-Based Drugs
RNA interference (RNAi) is a post-transcriptional gene silencing mechanism that regulates gene expression through sequence-specific degradation or translational inhibition of mRNA. Since its discovery, RNAi has emerged as a powerful therapeutic strategy due to its ability to selectively silence disease-causing genes that are often inaccessible to conventional small-molecule drugs. The clinical efficacy of RNAi technology is evidenced by the approval of multiple siRNA-based therapeutics for the treatment of various diseases. These include patisiran and vutrisiran for hereditary transthyretin amyloidosis, inclisiran for hypercholesterolemia, fitusiran for haemophilia A and B, givosiran for acute hepatic porphyria, and lumasiran and nedosiran for primary hyperoxaluria. Concurrently, a significant number of RNAi therapeutics are currently undergoing clinical trials for metabolic, cardiovascular, neurological, renal, pulmonary diseases and oncological area. Despite these advances, the clinical translation of RNAi therapeutics is limited by several challenges, including off-target effects, immune activation, and difficulties associated with efficient and targeted delivery. Ongoing research focuses on improving siRNA design, chemical modification, and delivery strategies in order to enhance specificity, reduce immunogenicity, and achieve effective delivery to target tissues. In conclusion, RNA interference has become more significant and expanding therapeutic approach with considerable implications for future drug development.
- 19 November 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (2) , 104064
Assessment of intranasal permeability and pharmacological activity of glyburide-loaded nanosuspension formulation for Alzheimer’s disease
- 19 November 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (2) , 104064
Assessment of intranasal permeability and pharmacological activity of glyburide-loaded nanosuspension formulation for Alzheimer’s disease
- 26 March 2024
- Published by Pleiades Publishing Ltd in Biology Bulletin
- Vol. 51 (3) , 700-710
Methylene Blue Attenuates Impaired Cognitive Functions and Reduces Hippocampal Aβ Levels and Oxidative Stress in D-Galactose-Induced Alzheimer’s Disease Mouse Model
Methylene blue (MB) has a long story of use and has been employed for various diseases, however, most of its current rekindled research is related to its function in the mitochondria. MB is gaining interest as a possible treatment because mitochondrial dysfunction is an apparent unifying pathogenic characteristic of a variety of neurodegenerative conditions. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by impairment of cognitive functions. This study aims to investigate whether MB treatment improves impaired cognitive functions and reduces hippocampal amyloid-β levels and oxidative stress in a D-galactose-induced AD mouse model. Twenty-four wild-type Balb/c mice were randomly divided into four groups (control, D-galactose-induced AD, MB-treated AD, and only MB-treated mice). Mice in the corresponding groups were injected with D-galactose (50 mg/kg, s.c.) for 60 days. In the MB treatment groups, the mice were treated with MB (2 mg/kg, orally) for the last 14 days of treatments. The Morris water maze test was used to assess spatial learning and memory functions. Amyloid β-42, malondialdehyde, superoxide dismutase, and nitric oxide levels in the hippocampi of mice were measured using ELISA and spectrophotometry. MB treatment improved impaired learning and memory functions induced by D-galactose administration and decreased amyloid β-42 concentration in the hippocampi of mice. Malondialdehyde level was found to decrease in MB-treated mice compared to D-galactose-induced AD mice in the hippocampus and plasma. The hippocampus of MB-treated mice displayed increased superoxide dismutase activity while decreased nitric oxide concentration compared to the ones of D-galactose-induced AD mice. MB has been shown to improve learning and memory impairments, as well as reduce Aβ-42 concentration and oxidative stress in the hippocampus of D-galactose-induced AD mice. The findings of this study demonstrate that MB may offer potential benefits as a repurposed agent for AD.
- 26 March 2024
- Published by Pleiades Publishing Ltd in Biology Bulletin
- Vol. 51 (3) , 700-710
Methylene Blue Attenuates Impaired Cognitive Functions and Reduces Hippocampal Aβ Levels and Oxidative Stress in D-Galactose-Induced Alzheimer’s Disease Mouse Model
Methylene blue (MB) has a long story of use and has been employed for various diseases, however, most of its current rekindled research is related to its function in the mitochondria. MB is gaining interest as a possible treatment because mitochondrial dysfunction is an apparent unifying pathogenic characteristic of a variety of neurodegenerative conditions. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by impairment of cognitive functions. This study aims to investigate whether MB treatment improves impaired cognitive functions and reduces hippocampal amyloid-β levels and oxidative stress in a D-galactose-induced AD mouse model. Twenty-four wild-type Balb/c mice were randomly divided into four groups (control, D-galactose-induced AD, MB-treated AD, and only MB-treated mice). Mice in the corresponding groups were injected with D-galactose (50 mg/kg, s.c.) for 60 days. In the MB treatment groups, the mice were treated with MB (2 mg/kg, orally) for the last 14 days of treatments. The Morris water maze test was used to assess spatial learning and memory functions. Amyloid β-42, malondialdehyde, superoxide dismutase, and nitric oxide levels in the hippocampi of mice were measured using ELISA and spectrophotometry. MB treatment improved impaired learning and memory functions induced by D-galactose administration and decreased amyloid β-42 concentration in the hippocampi of mice. Malondialdehyde level was found to decrease in MB-treated mice compared to D-galactose-induced AD mice in the hippocampus and plasma. The hippocampus of MB-treated mice displayed increased superoxide dismutase activity while decreased nitric oxide concentration compared to the ones of D-galactose-induced AD mice. MB has been shown to improve learning and memory impairments, as well as reduce Aβ-42 concentration and oxidative stress in the hippocampus of D-galactose-induced AD mice. The findings of this study demonstrate that MB may offer potential benefits as a repurposed agent for AD.
- Open Access
- 7 June 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 164, 114952
The novel KV7 channel activator URO-K10 exerts enhanced pulmonary vascular effects independent of the KCNE4 regulatory subunit
- 7 June 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 164, 114952
Open AccessThe novel KV7 channel activator URO-K10 exerts enhanced pulmonary vascular effects independent of the KCNE4 regulatory subunit
- 19 September 2022
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 77, 102166
Allopurinol treatment reduced vascular remodeling and improved vascular functions in monocrotaline-induced pulmonary hypertensive rats
- 19 September 2022
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 77, 102166
Allopurinol treatment reduced vascular remodeling and improved vascular functions in monocrotaline-induced pulmonary hypertensive rats
- Open Access
- 1 September 2022
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 38 (3) , 255-265
Anti-inflammatory effects of oral and intraperitoneal administration of cerium oxide nanoparticles on experimental hepatic ischemia-reperfusion injury
Objective: Hepatic ischemia-reperfusion (IR) injury occurs in liver surgery, resection, and transplantation. Reactive oxygen species (ROS) produced following IR starts the cascade of cell damage, necrosis/apoptosis, and proinflammatory responses by activating intracellular signaling cascade to drive hepatocellular damage. Cerium oxide nanoparticles (CONPs) act as anti-inflammatory and antioxidant agents. Thus, we evaluated the protective effects of oral (o.g.) and intraperitoneal (i.p.) administration of CONPs on hepatic IR injury. Material and Methods: Mice were randomly divided into five groups: control, sham, IR protocol, CONP+IR (i.p.), and CONP+IR (o.g.). Mouse hepatic IR protocol was applied to the animals in the IR group. CONPs (300 μg/kg) were administered 24 hours before IR protocol. Blood and tissue samples were taken after the reperfusion period. Results: Hepatic IR injury markedly increased enzyme activities, tissue lipid peroxidation, myeloperoxidase (MPO), xanthine oxidase (XO), nitrite oxide (NO), and tissue nuclear factor kappa-B (NF-κB) p65 levels, plasma pro-inflammatory cytokines, chemokines, and adhesion molecules while decreasing antioxidant markers and caused pathological changes in hepatic tissue. The expression of tumor necrosis factor alpha (TNF-α), matrix metalloproteinase 2 (MMP-2), and 9 increased, and tissue inhibitor matrix metalloproteinase 1 (TIMP-1) expression decreased in the IR group. Pretreatment with CONPs o.g. and i.p. 24 hours before hepatic ischemia improved the biochemical parameters above and alleviated the histopathological findings. Conclusion: Results of the present study demonstrate a significant reduction in liver degeneration by administering CONPs via i.p. and o.g. route in an experimental liver IR model, suggesting that CONPs have the extensive potential to prevent hepatic IR injury.
- 1 September 2022
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 38 (3) , 255-265
Open AccessAnti-inflammatory effects of oral and intraperitoneal administration of cerium oxide nanoparticles on experimental hepatic ischemia-reperfusion injury
Objective: Hepatic ischemia-reperfusion (IR) injury occurs in liver surgery, resection, and transplantation. Reactive oxygen species (ROS) produced following IR starts the cascade of cell damage, necrosis/apoptosis, and proinflammatory responses by activating intracellular signaling cascade to drive hepatocellular damage. Cerium oxide nanoparticles (CONPs) act as anti-inflammatory and antioxidant agents. Thus, we evaluated the protective effects of oral (o.g.) and intraperitoneal (i.p.) administration of CONPs on hepatic IR injury. Material and Methods: Mice were randomly divided into five groups: control, sham, IR protocol, CONP+IR (i.p.), and CONP+IR (o.g.). Mouse hepatic IR protocol was applied to the animals in the IR group. CONPs (300 μg/kg) were administered 24 hours before IR protocol. Blood and tissue samples were taken after the reperfusion period. Results: Hepatic IR injury markedly increased enzyme activities, tissue lipid peroxidation, myeloperoxidase (MPO), xanthine oxidase (XO), nitrite oxide (NO), and tissue nuclear factor kappa-B (NF-κB) p65 levels, plasma pro-inflammatory cytokines, chemokines, and adhesion molecules while decreasing antioxidant markers and caused pathological changes in hepatic tissue. The expression of tumor necrosis factor alpha (TNF-α), matrix metalloproteinase 2 (MMP-2), and 9 increased, and tissue inhibitor matrix metalloproteinase 1 (TIMP-1) expression decreased in the IR group. Pretreatment with CONPs o.g. and i.p. 24 hours before hepatic ischemia improved the biochemical parameters above and alleviated the histopathological findings. Conclusion: Results of the present study demonstrate a significant reduction in liver degeneration by administering CONPs via i.p. and o.g. route in an experimental liver IR model, suggesting that CONPs have the extensive potential to prevent hepatic IR injury.
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista de Nutrição
- Vol. 34
The effects of 5-hydroxytryptophan on carrageenan-induced mouse paw oedemas
Objective 5-Hydroxytryptophan is the precursor compound of serotonin biosynthesis. The oral absorption of 5-Hydroxytryptophan is close to 100% and, unlike serotonin, it crosses the blood-brain barrier freely. 5-Hydroxytryptophan has been used as a food supplement for many years to treat anxiety and depression. Recent studies have shown that 5-Hydroxytryptophan suppresses the pro-inflammatory mediators and is effective in some inflammatory diseases, such as arthritis and allergic asthma. However, the role of 5-Hydroxytryptophan supplements on acute peripheral inflammation has not been investigated yet. In this study, the in vivo anti-inflammatory activity of 5-Hydroxytryptophan was evaluated with a carrageenan-induced paw oedema test in mice. Methods For the investigation of the acute antiinflammatory activity, single oral doses of 5-Hydroxytryptophan (1.5, 5 and 20mg/kg) were given to mice 1.5 hours prior to the carrageenan test. For chronic activity, the same oral doses were administered daily for two weeks prior to the carrageenan test on the 14th day. To induce inflammation, 0.01mL of 2% carrageenan was injected into the paws of mice. Results Supplementation with 5-Hydroxytryptophan significantly reduced inflammation in a dose-independent manner which was irrespective of the duration of exposure (per cent inhibition in acute experiments was 35.4%, 20.9%, 24.0%, and per cent inhibition in chronic experiments was 29.5%, 35.3%, 40.8% for the doses of 1.5, 5, and 20mg/kg, respectively). Conclusion Our findings demonstrate for the first time that 5-HTP supplements have the potential of suppressing the measures of acute peripheral inflammation. It is suggested that, apart from several diseases where serotonin is believed to play an important role, including depression, patients with inflammatory conditions may also benefit from 5-HTP.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista de Nutrição
- Vol. 34
Open AccessThe effects of 5-hydroxytryptophan on carrageenan-induced mouse paw oedemas
Objective 5-Hydroxytryptophan is the precursor compound of serotonin biosynthesis. The oral absorption of 5-Hydroxytryptophan is close to 100% and, unlike serotonin, it crosses the blood-brain barrier freely. 5-Hydroxytryptophan has been used as a food supplement for many years to treat anxiety and depression. Recent studies have shown that 5-Hydroxytryptophan suppresses the pro-inflammatory mediators and is effective in some inflammatory diseases, such as arthritis and allergic asthma. However, the role of 5-Hydroxytryptophan supplements on acute peripheral inflammation has not been investigated yet. In this study, the in vivo anti-inflammatory activity of 5-Hydroxytryptophan was evaluated with a carrageenan-induced paw oedema test in mice. Methods For the investigation of the acute antiinflammatory activity, single oral doses of 5-Hydroxytryptophan (1.5, 5 and 20mg/kg) were given to mice 1.5 hours prior to the carrageenan test. For chronic activity, the same oral doses were administered daily for two weeks prior to the carrageenan test on the 14th day. To induce inflammation, 0.01mL of 2% carrageenan was injected into the paws of mice. Results Supplementation with 5-Hydroxytryptophan significantly reduced inflammation in a dose-independent manner which was irrespective of the duration of exposure (per cent inhibition in acute experiments was 35.4%, 20.9%, 24.0%, and per cent inhibition in chronic experiments was 29.5%, 35.3%, 40.8% for the doses of 1.5, 5, and 20mg/kg, respectively). Conclusion Our findings demonstrate for the first time that 5-HTP supplements have the potential of suppressing the measures of acute peripheral inflammation. It is suggested that, apart from several diseases where serotonin is believed to play an important role, including depression, patients with inflammatory conditions may also benefit from 5-HTP.
- 1 June 2020
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 17 (3) , 349-356
The Cardiopulmonary Effects of the Calcitonin Generelated Peptide Family
Cardiopulmonary diseases are very common among the population. They are high-cost diseases and there are still no definitive treatments. The roles of members of the calcitonin-gene related-peptide (CGRP) family in treating cardiopulmonary diseases have been studied for many years and promising results obtained. Especially in recent years, two important members of the family, adrenomedullin and adrenomedullin2/intermedin, have been considered new treatment targets in cardiopulmonary diseases. In this review, the roles of CGRP family members in cardiopulmonary diseases are investigated based on the studies performed to date.
- 1 June 2020
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 17 (3) , 349-356
The Cardiopulmonary Effects of the Calcitonin Generelated Peptide Family
Cardiopulmonary diseases are very common among the population. They are high-cost diseases and there are still no definitive treatments. The roles of members of the calcitonin-gene related-peptide (CGRP) family in treating cardiopulmonary diseases have been studied for many years and promising results obtained. Especially in recent years, two important members of the family, adrenomedullin and adrenomedullin2/intermedin, have been considered new treatment targets in cardiopulmonary diseases. In this review, the roles of CGRP family members in cardiopulmonary diseases are investigated based on the studies performed to date.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4208
Investigation of the relationship between montelukast treatment, asthma and depression-like behavior in mice
In 2008, FDA issued a warning about the neuropsychiatric side-effects of montelukast which is a commonly used treatment of asthma. The clinical studies have conflicting results and there are no experimental studies related to this issue. We have investigated the effect of montelukast on depression-like behaviour in a modified ovalbumin(OVA)-induced asthma model. Three OVA challenges were applied in two-week intervals for the persistence of chronic asthma and in treatment groups montelukast was given in drinking water. Depression-like behaviour was assessed by forced swim test (FST) at the end of each 3 OVA challenges, the lungs and plasma were isolated for histopathological examination and plasma montelukast measurement. OVA protocol lead to an inflammation response in the lungs after all challenges (inflammation scores were 5±0.8, 4.8±0.4, 4.7±0.7 for OVA and 2.7±0.3, 3.3±0.2, 2.2±0.2 for control groups respectively for 1st, 2nd and 3rd OVA challenges) which were augmented by montelukast treatment (3.8±0.9 in 2nd and 2.3±0.5 in 3rd challenge). The immobility time in FST was increased in asthmatic mice (133.2±13.4 in 2nd, 132.3±14.1 in 3rd challenges vs. control 84.9±8.9 and 73.4±12.8) which was also reduced by montelukast treatment (75.3±11.3 in 2nd and 58±16.1 in 3rd). Furthermore, chronic administration of montelukast to non-asthmatic mice had no effect in the immobility time. These results suggest that montelukast treatment may not be associated with depression-like behaviour and confirms the relationship between asthma and depression. However, more studies should be performed for better understanding the neuropsychiatric side-effects of montelukast.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4208
Investigation of the relationship between montelukast treatment, asthma and depression-like behavior in mice
In 2008, FDA issued a warning about the neuropsychiatric side-effects of montelukast which is a commonly used treatment of asthma. The clinical studies have conflicting results and there are no experimental studies related to this issue. We have investigated the effect of montelukast on depression-like behaviour in a modified ovalbumin(OVA)-induced asthma model. Three OVA challenges were applied in two-week intervals for the persistence of chronic asthma and in treatment groups montelukast was given in drinking water. Depression-like behaviour was assessed by forced swim test (FST) at the end of each 3 OVA challenges, the lungs and plasma were isolated for histopathological examination and plasma montelukast measurement. OVA protocol lead to an inflammation response in the lungs after all challenges (inflammation scores were 5±0.8, 4.8±0.4, 4.7±0.7 for OVA and 2.7±0.3, 3.3±0.2, 2.2±0.2 for control groups respectively for 1st, 2nd and 3rd OVA challenges) which were augmented by montelukast treatment (3.8±0.9 in 2nd and 2.3±0.5 in 3rd challenge). The immobility time in FST was increased in asthmatic mice (133.2±13.4 in 2nd, 132.3±14.1 in 3rd challenges vs. control 84.9±8.9 and 73.4±12.8) which was also reduced by montelukast treatment (75.3±11.3 in 2nd and 58±16.1 in 3rd). Furthermore, chronic administration of montelukast to non-asthmatic mice had no effect in the immobility time. These results suggest that montelukast treatment may not be associated with depression-like behaviour and confirms the relationship between asthma and depression. However, more studies should be performed for better understanding the neuropsychiatric side-effects of montelukast.